The National Organization for Rare Disorders (NORD®), the leading independent nonprofit organization representing Americans living with rare diseases, has announced the availability of new funding opportunities for studies focused on two rare diseases.
NORD’s Jayne Holtzer Rare Disease Research Grants Program provides seed funding to qualified researchers for translational or clinical studies related to the development of potential new diagnostics or treatments for rare diseases. Over the past thirty years, NORD grants have led to the development of two FDA-approved treatments and numerous peer-reviewed publications. The organization has awarded more than two hundred grants over that period, representing over $9 million in approved funding since the program’s launch in 1989.
The program currently is accepting proposals for scientific and/or clinical research studies of:
Appendix cancer and pseudomyxoma peritonei (PMP) — Two grants of up to $50,000 each.
Neuroendocrine cell hyperplasia of infancy (NEHI) — A single grant of up to $50,000.
The initial deadline for applications is August 25. NORD encourages all U.S. and international researchers interested in studying one or more of these diseases to review the complete application guidelines detailed in the request for proposals.
For more information about the Jayne Holtzer Rare Disease Research Grants Program and other rare disease research funding opportunities, see the National Organization for Rare Disorders website.